MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

MiNK Therapeutics, Inc.NASDAQ: INKT

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$3.

Context

  • Capital expenditures increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$0.75.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
-$3— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Capital Expenditures vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's LTM Mar 2026 capital expenditures of $3 is the 5th largest of the 9 companies compared; the peer median is $4.
INKT Competitors Peer median
Capital Expenditures for INKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$316.42K +110.9%——
EQEquillium, Inc.LTM Mar 2026$47K -32.9%-44.4%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$10K ———
GANXGain Therapeutics, Inc.LTM Mar 2026$8 -100.0%——
INKTMiNK Therapeutics, Inc.LTM Mar 2026$3 ———
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
VTVTvTv Therapeutics Inc.LTM Mar 2026$0 ——0.0%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$0 +100.0%—0.0%
Peer median (excluding INKT) $4+33.6%-44.4%0.0%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
Deferred Income Tax00000
Stock-Based Compensation1.74M3.03M3.86M1.81M2.67M
Change in Working Capital3.74M8.77M2.9M459.73K3.29M
Accounts Receivables00000
Inventory00000
Accounts Payables(152.04K)2.66M(1.92M)(1.18M)689.71K
Other Working Capital3.89M6.11M4.81M1.64M2.6M
Other Non-Cash Items11.83M(2.79M)(266.78K)(1.26M)424.63K
Operating Cash Flow(12.83M)(18.87M)(15.76M)(9.56M)(5.93M)
Capital Expenditures(248.98K)(250.05K)(73.56K)(4)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(248.98K)(250.05K)(73.56K)00
Debt Repayment9.46M005M0
Common Stock Issued39.8M005.8M14.9M
Common Stock Repurchased0(157.19K)(477.64K)00
Dividends Paid00000
Other Financing Activities1501.6K70.47K19.99K(173.35K)
Financing Cash Flow49.26M(155.6K)(407.17K)10.82M14.72M
Effect of Forex Changes16.9K19.39K(25.25K)(54.7K)(13.43K)
Net Change in Cash36.2M(19.25M)(16.27M)1.21M8.78M
Free Cash Flow(13.08M)(19.12M)(15.84M)(9.56M)(5.93M)

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.